Skip to content

Myocarditis and/or pericarditis following mRNA COVID-19 VACCination national surveillance study (MYCOVACC)

Myocarditis | COVID-19 Infection

There are many causes of myocarditis and/or pericarditis and although rare, there have been reported incidents after having COVID-19 infection or receiving mRNA COVID-19 vaccinations. Canadian and international data show a higher rate of myocarditis and/or pericarditis after receiving mRNA COVID-19 vaccinations than would normally be expected in the general population.

The purpose of this study is to collect information on how people who have this diagnosis in Canada are identified, treated, and assess how they do over the study duration. This may help to contribute to the overall understanding of this medical condition.

null

Conditions de participation

  • Sexe:

    Any

  • Âges admissibles:

    18 and up

Critères de participation

Inclusion Criteria:
You have received a COVID-19 vaccination or had a COVID-19 infection, in the past 42 days and have been diagnosed with myocarditis/pericarditis by a physician.

If your COVID-19 vaccination or the onset of your COVID -19 infection was greater than 42 days ago, you are still eligible to participate and you will enter the study timeline according to when you received the COVID-19 vaccination or were infected with COVID-19.

No alternative cause of the myocarditis/pericarditis.
Exclusion Criteria:
You have not been diagnosed with myocarditis or pericarditis, or another cause has been identified.

Lieu de l'étude

University of Alberta
University of Alberta
Edmonton, Alberta
Canada

Contactez l'équipe d'étude

Primary Contact

Laurie Haykowsky

[email protected]
null
Primary Contact

Quentin Kushnerik

[email protected]
null
Étude parrainée par
University of Alberta
Participants recherchés
Plus d'informations
ID de l'étude: Pro00137954